YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
ApexOnco Front Page
Recent articles
While Sutro shows why it’s shelved luvelta-T.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
